|
Vioxx®, also know as rofecoxib, has been voluntarily removed
from the market.
Increased risk of:
The FDA has stated that they have "acknowledged the voluntary
withdrawal from the market of Vioxx (chemical name rofecoxib), a
non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck
& Co. FDA today also issued a Public Health Advisory to inform
patients of this action and to advise them to consult with a physician
about alternative medications."
Vioxx is a NSAID (Non-Steroidal Anti-Inflammatory Drug) It is prescribed
for the relief of symptoms of the following:
- osteoarthritis
- management of acute pain in adults
- treatment of menstrual symptoms
- relief of rheumatoid arthritis symptoms (adults and children)
If you have taken Vioxx® and have had a heart attack, stroke
or blood clots, learn more about your options and get an instant
answer to your questions. Call today and speak with an Attorney:
1.800.838.0800.
We currently represent a young woman who took this drug for pain
management. Prior to taking the drug she was a healthy person. After
taking Vioxx she suffered a heart attack as a result of a blood
clot.
If this sounds like your situation or you had other problems from
this drug, then please contact us. Use our Instant
Answer Form.
|
$1.5 Million: Over the counter Pharmacy
cases. Two cases involving an over the counter drug. 2004
$5+ Million: Multiple pharmacy cases.
Involving damage caused by a prescription drug. 2004
"I was amazed at how the team at Burke and Eisner was able
to cut through it all, and successfully obtain the highest possible
compensation for my losses."
(NH Client)
FDA: FDA
Issues Public Health Advisory Recommending Limited Use of Cox-2
Inhibitors
FDA: Public
Health Advisory Non-Steroidal Anti-Inflammatory Drug Products (NSAIDS)
Yahoo: FDA
Urges Limited Use of Pfizer's Celebrex, Bextra
FDA:
Vioxx Voluntarily Withdrawn; Health Advisory Issued
Additional
FDA Information regarding Vioxx
FDA
health advisory
FDA
Vioxx press release
The FDA has created a question and answer page. You can get
basic information here.
Brief
Forbes Article from August 2004
|
